Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

NITROSTAT® Highlights (nitroglycerin)


These highlights do not include all the information needed to use NITROSTAT safely and effectively. See full prescribing information for NITROSTAT

NITROSTAT (nitroglycerin) sublingual tablet
Initial U.S. Approval: 1981


NITROSTAT is a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (1)


  • At the onset of an attack, administer one tablet under the tongue or buccal pouch. One additional tablet may be administered every 5 minutes as needed. No more than 3 total tablets are recommended within a 15 minute period. (2)
  • If chest pain persists after three tablets, seek prompt medical attention. (2)
  • May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. (2)


Sublingual tablets, 0.3 mg; 0.4 mg; 0.6 mg (3)


  • Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1)
  • Severe anemia (4.2)
  • Increased intracranial pressure (4.3)
  • Hypersensitivity to NITROSTAT or to other nitrates or nitrites or any excipient (4.4)
  • Circulatory failure and shock (4.5)


  • Tolerance: Excessive use may lead to tolerance. (5.1)
  • Hypotension: Severe hypotension may occur. (5.2)


Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use. (7.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 2/2018

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

*9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or